Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer's Disease
Lantheus announced results from two pivotal Phase 3 studies evaluating TAUKLARIFY PET imaging, also known as MK-6240. The studies supported FDA use in adults with cognitive impairment being evaluated for Alzheimer’s disease to identify neurofibrillary tangle pathology.
Why it matters — The announcement concerns clinical evidence for a Lantheus imaging product in the Alzheimer’s disease evaluation setting.